Correlation of response with overall survival (OS) for nivolumab vs everolimus in advanced renal cell carcinoma (aRCC): Results from the phase III CheckMate 025 study

被引：0

作者：

Gruenwald, V ^{[1
]}

Motzer, R. J. ^{[2
]}

Sharma, P. ^{[3
]}

Escudier, B. ^{[4
]}

McDermott, D. F. ^{[5
]}

George, S. ^{[6
]}

Srinivas, S. ^{[7
]}

Tykodi, S. S. ^{[8
,9
]}

Sosman, J. A. ^{[10
]}

Plimack, E. R. ^{[11
]}

Nathan, P. ^{[12
]}

Tomita, Y. ^{[13
]}

Zhao, H. ^{[14
]}

Waxman, I. M. ^{[15
]}

Hammers, H. J. ^{[16
]}

机构：

[1] Hannover Med Sch, Hannover, Germany

[2] Mem Sloan Kettering Canc Ctr, 1275 York Ave, New York, NY 10021 USA

[3] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA

[4] Inst Gustave Roussy, Villejuif, France

[5] Dana Farber Harvard Canc Ctr, Beth Israel Deaconess Med Ctr, Boston, MA USA

[6] Roswell Pk Canc Inst, Buffalo, NY 14263 USA

[7] Stanford Canc Inst, Stanford, CA USA

[8] Univ Washington, Seattle, WA 98195 USA

[9] Fred Hutchinson Canc Res Ctr, 1124 Columbia St, Seattle, WA 98104 USA

[10] Vanderbilt Univ, Med Ctr, Nashville, TN USA

[11] Fox Chase Canc Ctr, 7701 Burholme Ave, Philadelphia, PA 19111 USA

[12] Mt Vernon Canc Ctr, Northwood, Middx, England

[13] Niigata Univ, Niigata, Japan

[14] Bristol Myers Squibb, Pennington, NJ USA

[15] Bristol Myers Squibb, Lawrenceville, NJ USA

[16] Johns Hopkins Sidney Kimmel Comprehens Canc Ctr, Baltimore, MD USA

来源：

ONCOLOGY RESEARCH AND TREATMENT | 2016年 / 39卷

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

P878

引用

页码：264 / 265

页数：2

共 50 条

[1] Correlation of response with overall survival (OS) for nivolumab vs everolimus in advanced renal cell carcinoma (aRCC): Results from the phase III CheckMate 025 study
Motzer, Robert J.
Sharma, Padmanee
Escudier, Bernard J.
McDermott, David F.
George, Saby
Srinivas, Sandy
Tykodi, Scott S.
Sosman, Jeffrey Alan
Plimack, Elizabeth R.
Nathan, Paul D.
Gruenwald, Viktor
Tomita, Yoshihiko
Zhao, Huanyu
Waxman, Ian M.
Hammers, Hans J.
JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
[2] Quality of life (QoL) and overall survival (OS) in patients (pts) with advanced clear-cell renal cell carcinoma (aRCC) treated with nivolumab (NIVI) vs. everolimus (EVE) in the phase III CheckMate 025 study
Cella, David
Gruenwald, Viktor
Nathan, Paul D.
Doan, Justin
Dastani, Homa
Taylor, Fiona
Bennett, Bryan
DeRosa, Michael
Berry, Scott
Broglio, Kristine
Berghorn, Elmer
Motzer, Robert J.
JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
[3] Improvements in quality of life and overall survival in patients with advanced renal cell carcinoma treated with nivolumab vs everolimus in the phase Ill CheckMate 025 study
Gruenwald, V
Cella, D.
Nathan, P.
Doan, J.
Dastahi, H.
Taylor, F.
Bennett, B.
DeRosa, M.
Berry, S.
Broglio, K.
Berghorn, E.
Motzer, R. J.
ONCOLOGY RESEARCH AND TREATMENT, 2016, 39 : 265 - 265
[4] Two-year efficacy and safety update from the phase III CheckMate 025 study of nivolumab versus everolimus in patients with advanced renal cell carcinoma (aRCC)
Plimack, Elizabeth R.
Motzer, Robert J.
Escudier, Bernard
Sharma, Padmanee
Mcdermott, David F.
George, Saby
Hammers, Hans J.
Carducci, Michael
Tykodi, Scott S.
Sosman, Jeffrey A.
Choueiri, Toni K.
Donskov, Frede
Gurney, Howard
Gauler, Thomas C.
Ueda, Takeshi
Zhao, Huanyu
Berghorn, Elmer
Wagstaff, John
BJU INTERNATIONAL, 2016, 118 : 11 - 12
[5] Three-Year Efficacy and Safety Update From the Phase III Checkmate 025 Study of Nivolumab (NIVO) v Everolimus (EVE) in Patients With Advanced Renal Cell Carcinoma (aRCC)
Sharma, P.
Tykodi, S. S.
Escudier, B.
Carducci, M.
Oudard, S.
Hammers, H. J.
George, S.
Gauna, D. C.
Alva, A. S.
Richardet, M. E.
Chevreau, C.
Plimack, E. R.
Srinivas, S.
Procopio, G.
Sosman, J. A.
McDermott, D.
Choueiri, T. K.
Gauler, T.
Berghorn, E.
Yang, L.
Motzer, R.
ONCOLOGY RESEARCH AND TREATMENT, 2018, 41 : 78 - 78
[6] Treatment beyond progression with nivolumab (nivo in patients (pts) with advanced renal cell carcinoma (aRCC) in the phase III CheckMate 025 study.
Escudier, Bernardi.
Motzer, Roberti.
Sharma, Padmanee
Wagstaff, John
Plimack, Elizabeth R.
Hammers, Hans J.
Donskov, Frede
Gurney, Howard
Sosman, Jeffrey Alan
Zalewski, Pawel
Harmenberg, Ulrika
McDermott, David F.
Choueiri, Toni K.
Richardet, Martin Eduardo
Tomita, Yoshihiko
Ravaud, Alain
Doan, Justin
Zhao, Huanyu
Hardy, Helene
George, Saby
JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
[7] Nivolumab versus everolimus in advanced renal cell carcinoma: Japanese subgroup analysis from the CheckMate 025 study
Tomita, Yoshihiko
Fukasawa, Satoshi
Shinohara, Nobuo
Kitamura, Hiroshi
Oya, Mototsugu
Eto, Masatoshi
Tanabe, Kazunari
Kimura, Go
Yonese, Junji
Yao, Masahiro
Motzer, Robert J.
Uemura, Hirotsugu
McHenry, M. Brent
Berghorn, Elmer
Ozono, Seiichiro
JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 2017, 47 (07) : 639 - 646
[8] CheckMate 025: a randomized, open-label, phase III study of nivolumab (NIVO) versus everolimus (EVE) in advanced renal cell carcinoma (RCC)
Sharma, P.
Escudier, B.
McDermott, D. F.
George, S.
Hammers, H. J.
Srinivas, S.
Tykodi, S. S.
Sosman, J. A.
Procopio, G.
Plimack, E. R.
Castellano, D.
Gurney, H.
Donskov, F.
Bono, P.
Wagstaff, J.
Gauler, T. C.
Ueda, T.
Xu, L. A.
Waxman, I. M.
Motzer, R. J.
EUROPEAN JOURNAL OF CANCER, 2015, 51 : S708 - S708
[9] Nivolumab is a new Therapy Option for metastasized Renal Cell Carcinoma Results of the Phase-III-Study CheckMate 025
Nuhn, Philipp
Bolenz, Christian
ONKOLOGE, 2017, 23 (03): : 232 - 233
[10] CheckMate 025: a randomized, open-label, phase Ill study of nivolumab versus everolimus in advanced renal cell carcinoma (RCC)
Motzer, Robert J.
Escudier, Bernard
Mcdermott, David F.
George, Saby
Hammers, Hans J.
Srinivas, Sandhya
Tykodi, Scott S.
Sosman, Jeffrey A.
Procopio, Giuseppe
Plimack, Elizabeth R.
Castellano, Daniel
Gurney, Howard
Donskov, Frede
Bono, Petri
Wagstaff, John
Gauler, Thomas C.
Ueda, Takeshi
Xu, Li-An
Waxman, Ian M.
Sharma, Padmanee
BJU INTERNATIONAL, 2015, 116 : 17 - 17

← 1 2 3 4 5 →